Home » The Sleep Aids Market to see digitized data collection at a CAGR of 4.2%

The Sleep Aids Market to see digitized data collection at a CAGR of 4.2%

by Soft2share.com

The Sleep Aids Market is slated to grow on a gracious note (US$ 40.1 Bn) between 2020 and 2025. Wearable technology is bound to come up as one of the prospective solutions for ascertaining assistive healthcare services for everyone. The common applications are inclusive of managing several health conditions through wearable devices, preventive care to ICU and elderly patients, and offering quality remote care to various patients at remote areas or care homes, and likewise. This would be the conduct of Sleep Aids Market in the forecast period.

The global sleep aids market is worth US$ 25.8 Bn at present, and The market for sleep aids is expected to reach US$ 40.1 Bn by 2031, while expanding at a CAGR of 4.5%.

Request for a Sample Copy@ https://www.persistencemarketresearch.com/samples/2832

Increasing prevalence of sleep-related disorders, changing lifestyles, obesity, and increasing aging population, together with technology advancements with the launch of innovative devices are some of the factors driving demand for sleep aids.

Increasing demand for sleeping pills due to modern lifestyles is one of the major factor driving demand for sleep aids. Stressful pace of life is found to be the main characteristic of modern lifestyle, thus increasing the incidence of sleep-related disorders. According to the Centers for Disease Control and Prevention (CDC) 2020 report, one-third of the U.S. population gets less than the recommended amount of sleep on a regular basis.

Market Competition

New product launches and acquisitions have emerged as a key growth strategy adopted by some of the leading manufacturers of sleep aids. By focusing on these strategies, key stakeholders are expanding their geographic footprints and strengthening their existing product portfolios.

  • 04-Feb-2020, Merck & Co/MSD claimed FDA approval for a new use of its insomnia drug Belsomra, treating sleep disruption in people with mild-to-moderate Alzheimer’s disease.
  • In January 2019, GSK announced that it completed the acquisition of Tesaro for approximately US$ 5.1 Bn.
  • In 2018, Philips acquired NightBalance, a digital health company in the Netherlands, which has developed an innovative, easy-to-use device to treat positional obstructive sleep apnea and positional snoring.
  • In August 2017, Sanofi S.A. announced the acquisition of Protein Sciences, a vaccines biotechnology company based in Meriden, Connecticut, in the United States.

Related Articles

Leave a Comment